MCID: SML001
MIFTS: 52

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15 17
Small Cell Carcinoma, Intermediate Cell 12 71
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 71
Carcinoma, Small Cell 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 49 C4099
SNOMED-CT 67 5958006
UMLS 71 C0149925 C0262584 C0334239

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to ovarian small cell carcinoma and lung combined type small cell carcinoma. An important gene associated with Small Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Pembrolizumab and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and cervix, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Basal Cell Carcinoma Large Cell Carcinoma
Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 960)
# Related Disease Score Top Affiliating Genes
1 ovarian small cell carcinoma 35.1 SYP SMARCA4 MUC1
2 lung combined type small cell carcinoma 35.1 SYP NCAM1
3 cervix small cell carcinoma 34.9 SYP ENO2 CHGA
4 thymus small cell carcinoma 34.8 SYP ENO2 CHGA
5 ureter small cell carcinoma 34.7 SYP NCAM1 ENO2 CHGA
6 gastric small cell carcinoma 34.7 SYP NCAM1 ENO2 CHGA
7 small cell carcinoma of the bladder 34.7 SYP NKX2-1 KRT7 KRT20 ENO2 CHGA
8 gallbladder small cell carcinoma 34.6 SYP NCAM1 ENO2 CHGA
9 laryngeal small cell carcinoma 34.5 SYP NKX2-1 NCAM1 KRT7 CHGA
10 endometrial small cell carcinoma 34.5 SYP PTPRC NCAM1 KIT ENO2 CHGA
11 lung large cell carcinoma 33.0 SYP NCAM1 CHGA
12 small cell cancer of the lung 32.3 TP53 SYP PTPRC PTEN NKX2-1 NCAM1
13 merkel cell carcinoma 31.9 TP53 SYP PTPRC NKX2-1 NCAM1 MUC1
14 prostate cancer 31.3 TP53 TMPRSS2 SMARCA4 PTEN MUC1 KRAS
15 lung oat cell carcinoma 31.3 SYP GRP ENO2 CHGA CALCA
16 in situ carcinoma 31.3 TP53 PTEN MUC1 EGFR
17 squamous cell carcinoma 31.2 TP53 PTEN MUC1 KRT19 EGFR
18 rhabdoid cancer 31.1 TP53 SYP SMARCA4 ENO2
19 lung cancer 31.0 TP53 SYP SMARCA4 PTEN NKX2-1 NCAM1
20 pulmonary large cell neuroendocrine carcinoma 31.0 SYP NCAM1 CHGA
21 carcinoid tumors, intestinal 30.9 SYP NKX2-1 ENO2 CHGA
22 rhabdoid tumor predisposition syndrome 1 30.9 TP53 SYP PTPRC MUC1
23 gallbladder adenocarcinoma 30.9 TP53 KRT20 EGFR
24 sex cord-gonadal stromal tumor 30.9 NKX2-1 MUC1 KRT7
25 atypical teratoid rhabdoid tumor 30.8 TP53 SYP SMARCA4 MUC1 CHGA
26 thyroid carcinoma 30.8 TP53 PTEN NKX2-1 CALCA
27 transitional cell carcinoma 30.8 TP53 PTEN KRT7 KRT20 KRT19 KLK3
28 thyroid gland medullary carcinoma 30.8 SYP ENO2 CHGA CALCA
29 adenocarcinoma 30.8 TP53 PTEN NKX2-1 MUC1 KRT7 KRT20
30 adenoma 30.7 TP53 MUC1 KRT7 KRAS CHGA
31 ductal carcinoma in situ 30.7 TP53 PTEN MUC1 EGFR
32 bladder cancer 30.7 TP53 PTEN MUC1 KRT20 KRT19 KRAS
33 endodermal sinus tumor 30.7 KLK3 KIT CHGA
34 endocervical adenocarcinoma 30.7 TP53 MUC1 KRT7 KRT20
35 lung disease 30.7 TP53 NKX2-1 MUC1 GRP ENO2 EGFR
36 barrett esophagus 30.6 TP53 KRT7 KRT20 EGFR
37 large cell neuroendocrine carcinoma 30.6 SYP NKX2-1 NCAM1 KRT7 KRT20 KIT
38 cystitis 30.6 TP53 KRT7 KRT20 KIT
39 sertoli-leydig cell tumor 30.6 SYP MUC1 KRT7 ENO2
40 spindle cell carcinoma 30.6 SYP MUC1 KRT7 KRT19 ENO2 CHGA
41 achalasia 30.6 TP53 KIT ENO2
42 constipation 30.6 KIT GRP CHGA CALCA
43 cholecystitis 30.5 TP53 MUC1 EGFR
44 cystadenocarcinoma 30.5 TP53 PTPRC MUC1 KRT7
45 malignant pleural mesothelioma 30.5 TP53 NKX2-1 MUC1 EGFR
46 leiomyosarcoma 30.5 TP53 PTPRC MUC1 KIT ENO2
47 neuroendocrine tumor 30.5 SYP NKX2-1 NCAM1 KRT20 KRT19 GRP
48 granular cell tumor 30.5 SYP NKX2-1 ENO2
49 mucinous cystadenocarcinoma 30.5 PTPRC MUC1 KRT7 KRT20
50 appendix adenocarcinoma 30.5 SYP KRT7 KRT20 KRAS

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.03 EGFR KRAS MUC1 NCAM1
2 Decreased viability GR00106-A-0 10.03 KRAS
3 Decreased viability GR00221-A-1 10.03 EGFR KRAS
4 Decreased viability GR00221-A-2 10.03 KRAS
5 Decreased viability GR00221-A-4 10.03 EGFR
6 Decreased viability GR00301-A 10.03 KRAS
7 Decreased viability GR00381-A-1 10.03 KRAS
8 Decreased viability GR00402-S-2 10.03 EGFR KRAS MUC1 NCAM1
9 Decreased viability in esophageal squamous lineage GR00235-A 9.65 CHGA KIT KLK3 KRAS KRT7 NKX2-1
10 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR KRAS KRT7 NCAM1 PTEN

MGI Mouse Phenotypes related to Small Cell Carcinoma:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 EGFR ENO2 KIT KRAS KRT19 KRT7
2 cardiovascular system MP:0005385 10.22 CHGA EGFR KIT KRAS KRT19 NKX2-1
3 nervous system MP:0003631 10.21 CHGA EGFR ENO2 GRP KIT KRAS
4 endocrine/exocrine gland MP:0005379 10.2 CHGA EGFR KIT KRAS KRT19 NKX2-1
5 digestive/alimentary MP:0005381 10.13 EGFR KIT KRAS KRT19 NKX2-1 PTEN
6 neoplasm MP:0002006 10.1 EGFR KIT KRAS KRT19 NKX2-1 PTEN
7 craniofacial MP:0005382 10.04 EGFR ENO2 KIT KRAS KRT19 SMARCA4
8 liver/biliary system MP:0005370 10.03 EGFR KIT KRAS KRT19 PTEN PTPRC
9 normal MP:0002873 10 EGFR KIT KRAS KRT19 NKX2-1 PTEN
10 no phenotypic analysis MP:0003012 9.92 CHGA EGFR KIT KRAS KRT19 NKX2-1
11 pigmentation MP:0001186 9.63 EGFR KIT KRAS PTEN SMARCA4 TP53
12 renal/urinary system MP:0005367 9.61 CHGA EGFR KIT KRAS KRT7 PTEN
13 respiratory system MP:0005388 9.36 EGFR ENO2 KIT KRAS KRT19 NKX2-1

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
3
nivolumab Approved Phase 3 946414-94-4
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
8
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
9
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Durvalumab Approved, Investigational Phase 3 1428935-60-7
12
Osimertinib Approved Phase 3 1421373-65-0 71496458
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
15 Amrubicin Investigational Phase 3 110267-81-7
16
Tremelimumab Investigational Phase 3 745013-59-6
17 Pharmaceutical Solutions Phase 3
18 Immunoconjugates Phase 3
19 Topoisomerase Inhibitors Phase 3
20 Antibodies, Monoclonal Phase 3
21 Folic Acid Antagonists Phase 3
22 Angiogenesis Inhibitors Phase 3
23 Antineoplastic Agents, Immunological Phase 3
24 Vitamin B Complex Phase 3
25 Vitamin B9 Phase 3
26 Folate Phase 3
27 Immunoglobulins Phase 3
28 Antibodies Phase 3
29 Albumin-Bound Paclitaxel Phase 3
30 Antimitotic Agents Phase 3
31 Etoposide phosphate Phase 3
32 Podophyllotoxin Phase 3 518-28-5
33
Apatinib Phase 3 811803-05-1
34 Endothelial Growth Factors Phase 3
35 Immunoglobulin G Phase 3
36 Hematinics Phase 3
37 Epoetin alfa Phase 3 113427-24-0
38
Pasireotide Approved Phase 2 396091-73-9 9941444
39
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
40
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
41
Vinblastine Approved Phase 2 865-21-4 13342 241903
42
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
43
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
46
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
48
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
49
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
50
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631

Interventional clinical trials:

(show top 50) (show all 241)
# Name Status NCT ID Phase Drugs
1 A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
2 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
3 Randomized Study Comparing Two Strategies Carboplatin and Etoposide Topotecan in Patients With SCLC on the Second Row With Relapsed at Least Three Months After Initial Response to Chemotherapy With Platinum-etoposide 6 Cycles Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
4 The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
5 Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC) Completed NCT00349492 Phase 3 IP
6 A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
7 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
8 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
9 AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
10 A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy Completed NCT00270166 Phase 3 epoetin alfa
11 A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer Recruiting NCT03699956 Phase 3 Cisplatin/carboplatin plus etoposide
12 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Recruiting NCT03811002 Phase 2, Phase 3 Atezolizumab;Carboplatin;Cisplatin;Etoposide
13 Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer Recruiting NCT02688036 Phase 3
14 A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Recruiting NCT03703297 Phase 3 Durvalumab;Tremelimumab
15 Anlotinib Combined With Sintilimab as Third-line Treatment or Beyond in Patients With Small Cell Lung Cancer Recruiting NCT04192682 Phase 2, Phase 3 Anlotinib Hydrochloride
16 Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer Recruiting NCT02635009 Phase 2, Phase 3
17 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
18 PARAT PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study Recruiting NCT03632603 Phase 3
19 A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE) Active, not recruiting NCT03061812 Phase 3 Rovalpituzumab tesirine;Topotecan
20 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers Active, not recruiting NCT02595944 Phase 3
21 A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN) Active, not recruiting NCT03043872 Phase 3 Durvalumab;Tremelimumab;Carboplatin;Cisplatin;Etoposide
22 A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer Not yet recruiting NCT04155034 Phase 3
23 A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy Not yet recruiting NCT02875457 Phase 3 apatinib;etoposide and cisplatin;placebo;etoposide and cisplatin
24 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT04181060 Phase 3 Osimertinib
25 Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Not yet recruiting NCT04092283 Phase 3 Carboplatin;Cisplatin;Etoposide;Paclitaxel;Pemetrexed;Pemetrexed Disodium
26 Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) Terminated NCT00310232 Phase 3 Epoetin Alfa
27 A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung Withdrawn NCT00006344 Phase 3
28 The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial Withdrawn NCT01058902 Phase 3 Aspirin 75 mg
29 Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer Unknown status NCT01635400 Phase 2 Irinotecan
30 Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer Unknown status NCT01900951 Phase 2 Temozolomide
31 Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma Unknown status NCT01574729 Phase 2 Surgery combined with rAd-p53 gene therapy
32 Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy Unknown status NCT02262897 Phase 2 Nab-paclitaxel
33 Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2 Unknown status NCT00906061 Phase 2 Gemcitabine and Docetaxel
34 Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer Unknown status NCT01592422 Phase 2
35 Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma Unknown status NCT00625352 Phase 2 Gemcitabine, UFT
36 A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer Unknown status NCT01417806 Phase 2 Topotecan and Pasireotide
37 Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Unknown status NCT01027676 Phase 1, Phase 2 Study treatment
38 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
39 Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin Unknown status NCT02687958 Phase 2 Everolimus
40 Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) Completed NCT00298896 Phase 2 SNS-595
41 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
42 Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer Completed NCT00308529 Phase 2 irinotecan;carboplatin;bevacizumab
43 An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer Completed NCT00412880 Phase 2 BI 2536
44 Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer Completed NCT00191750 Phase 2 Pemetrexed
45 A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00294931 Phase 2 irinotecan;carboplatin;bevacizumab
46 Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer Completed NCT00046787 Phase 2 OSI-211 (Liposomal Lurtotecan)
47 A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Completed NCT00305942 Phase 2 Topotecan;carboplatin
48 A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial) Completed NCT00391248 Phase 2 Erlotinib
49 A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy Completed NCT00375193 Phase 2 Amrubicin
50 A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Completed NCT00284154 Phase 2 Vinflunine

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

40
Lung, Prostate, Cervix, Breast, Ovary, Bone, Brain

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 6707)
# Title Authors PMID Year
1
Primary small cell carcinoma of the ureter with hydronephrosis: A case report. 61
31908961 2020
2
Cytomorphologic features of small cell carcinoma of lung in effusion fluid using a liquid-based cytology technique. 61
31820590 2020
3
Pulmonary Neuroendocrine Tumors. 61
32005434 2020
4
Small cell carcinoma of the uterine cervix: a multi-institutional experience. 61
31792086 2020
5
Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. 61
31676123 2020
6
The Russian Radiobiological Human Tissue Repository: characteristics of biological specimens donated by nuclear workers with lung cancer. 61
31976795 2020
7
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor. 61
31030230 2020
8
Spinal Epidural Hematoma Associated with Epidural Metastasis After Minor Trauma. 61
31568906 2020
9
Desmoplastic small round cell tumor showing solid proliferation with limited desmoplasia and confusing immunohistochemical findings: an autopsy report. 61
31907620 2020
10
Lung Cancer in a Tertiary Hospital in Nepal: Clinical-Radiological Profile and Histological Subtypes. 61
32001849 2020
11
Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil. 61
31967271 2020
12
Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small-cell carcinoma of the lung. 61
30791855 2020
13
[Primary Ureteral Small Cell Carcinoma with Multiple Recurrences and Metastases in the Early Postoperative Period : A Case Report]. 61
32028751 2020
14
Rare case of remission of a patient with small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) stage IV: Case report. 61
31978720 2020
15
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature. 61
32011517 2020
16
Cervix neuroendocrine carcinoma presenting with severe hypokalemia and Cushing's syndrome. 61
31970585 2020
17
Karyomegalic Interstitial Nephritis: Cancer Risk Following Transplantation. 61
31655823 2020
18
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. 61
31871155 2020
19
Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. 61
31982182 2020
20
Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough. 61
31995804 2020
21
Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. 61
31391295 2019
22
Adrenocorticotropic Hormone-producing Extrapulmonary Small Cell Carcinoma of the Breast. 61
32025410 2019
23
[A Case of Small Cell Carcinoma of the Breast]. 61
31879410 2019
24
Small cell carcinoma of the bladder presenting with paraneoplastic syndrome of inappropriate antidiuretic hormone. 61
31888898 2019
25
Fungating Anal Mass: Extrapulmonary Small Cell Carcinoma Masquerading as a Hemorrhoid. 61
31848872 2019
26
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. 61
31954538 2019
27
Neuroendocrine Tumors of the Lung: Updates and Diagnostic Pitfalls. 61
31672294 2019
28
Evaluation of metastases to the pancreas with fine needle aspiration: A case series from a single centre with review of the literature. 61
31788890 2019
29
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). 61
31654836 2019
30
Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract. 61
31876605 2019
31
Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques? 61
31651105 2019
32
[Pathological and molecular features of malignancies underlined by BAF complexes inactivation]. 61
31255411 2019
33
Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can Brown do for you? 61
31857137 2019
34
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. 61
31844183 2019
35
Small Cell Carcinoma in the Head and Neck. 61
31161776 2019
36
Bilateral Cavernous Sinus Syndrome, Pituitary Macroadenoma, and Postoperative Loss of Vision: A Case Report. 61
31449072 2019
37
The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis. 61
30360020 2019
38
Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy. 61
31327828 2019
39
Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. 61
31561203 2019
40
Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery. 61
31720896 2019
41
Pleural small cell carcinoma with massive pleural effusion: A case report. 61
31770288 2019
42
Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study. 61
31518071 2019
43
Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study. 61
31752922 2019
44
Small-cell carcinoma-associated ovarian mucinous carcinoma: A case report and literature review. 61
31585810 2019
45
Primary small cell carcinoma of the upper urinary tract: A case report. 61
31467857 2019
46
The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung. 61
31206846 2019
47
Postoperative adjuvant radiation improves local control in surgically treated FIGO stage I-II small cell carcinoma of the cervix. 61
31722727 2019
48
How can non-small cell carcinoma of the lung be typed accurately for optimum personalised cancer therapy? 61
31696606 2019
49
A Case of Sclerosing Mesenteritis Mimicking IgG4-related Disease. 61
31708540 2019
50
Outcome of treatment in patients with small cell lung cancer in poor performance status. 61
31282251 2019

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 PTPRC NCAM1 KRT7 KRT20 KRT19 KRAS
2
Show member pathways
13.2 TP53 SMARCA4 NCAM1 MUC1 KRAS KIT
3 12.57 TP53 PTEN KRAS KLK3 KIT EGFR
4
Show member pathways
12.51 TP53 PTEN KRAS KIT EGFR
5
Show member pathways
12.45 TP53 TMPRSS2 PTEN KRAS KLK3 KIT
6
Show member pathways
12.4 TP53 SMARCA4 PTEN KRAS KIT EGFR
7
Show member pathways
12.36 TP53 MUC1 KRAS EGFR
8 12.36 SYP NKX2-1 NCAM1 ENO2 CALCA
9 11.83 TP53 SMARCA4 PTEN EGFR
10 11.67 TP53 PTEN KRAS EGFR
11 11.62 PTPRC NCAM1 KIT
12 11.6 SYP SMARCA4 NCAM1
13 11.56 PTPRC NCAM1 KIT
14 11.54 TP53 SMARCA4 PTEN KRAS EGFR
15 11.53 TP53 KRAS EGFR
16 10.86 TP53 PTEN KRAS KIT EGFR

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 SMARCA4 MUC1 KLK3 KIT GRP ENO2
2 cytoplasmic side of plasma membrane GO:0009898 9.13 PTPRC PTEN KIT

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 TP53 PTEN NKX2-1 KRAS KIT
2 hematopoietic progenitor cell differentiation GO:0002244 9.54 TP53 PTPRC KIT
3 positive regulation of MAP kinase activity GO:0043406 9.5 KRAS KIT EGFR
4 cerebral cortex cell migration GO:0021795 9.48 NKX2-1 EGFR
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 EGFR
6 bone marrow development GO:0048539 9.43 TP53 PTPRC
7 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 MUC1
8 mast cell chemotaxis GO:0002551 9.16 KIT CHGA
9 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.96 GRP CHGA
10 mast cell cytokine production GO:0032762 8.62 KIT CHGA

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 p53 binding GO:0002039 8.8 TP53 SMARCA4 MUC1

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....